Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.8333.

Several research analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada dropped their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $6.64 on Friday. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.75. The stock has a market cap of $121.58 million, a PE ratio of -0.46 and a beta of 0.21. The firm has a fifty day moving average price of $6.62 and a 200 day moving average price of $5.96.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The business had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Large investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC purchased a new position in Karyopharm Therapeutics during the third quarter worth approximately $164,000. Bridgeway Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $163,000. Bank of America Corp DE lifted its position in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares in the last quarter. Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $45,000. Finally, Silverback Asset Management LLC grew its stake in Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after acquiring an additional 20,000 shares during the period. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.